No Data
JUNSHI BIO (688180.SH): After integrating with Deepseek, further pilot training for marketing employees and virtual practice has been initiated.
On March 10, Gelonghui reported that JUNSHI BIO (688180.SH) stated on the interactive platform that the company's digital transformation consistently adheres to the fundamental principle of "value-oriented, pragmatic innovation", ensuring that every digital investment corresponds to quantifiable business value output. By strategically deploying AI technology, the company aims to achieve both cost reduction and efficiency improvement alongside business innovation. Therefore, in 2024, the company has chosen an active and pragmatic strategy to promote the implementation of AI technology. The company has trained and deployed an AI translation platform based on large model technology, which has replaced over 80% of scientific literature, clinical trials, quality management, intellectual property, and other fields.
Is Shanghai Junshi Biosciences (HKG:1877) Using Too Much Debt?
Junshi Biotech: Junshi Biotech 2024 Annual Performance Report Announcement
Junshi Biotech 2024 Annual Results Report Announcement
JUNSHI BIO: INSIDE INFORMATION -2024 PRELIMINARY RESULTS
JUNSHI BIO (688180.SH): Net loss of 1.28 billion yuan in 2024.
On February 27, Gelonghui reported that JUNSHI BIO (688180.SH) announced its 2024 annual performance preliminary report, with total revenue of 1,948.3173 million yuan, an increase of 29.67% year-on-year, and a net income attributable to the parent company's owners of -1,282.2792 million yuan. During the reporting period, the company's revenue increased mainly due to the sales revenue of commercialized Pharmaceuticals compared to the same period last year. By the end of the reporting period, the company had already owned Trepulimab injection (trade name: Tuoyi), Adalimumab injection (trade name: Junmaikang), Dextromethorphan hydrobromide tablets (trade name: Mindewei), and Angorin.
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%
